Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,405.66 +470.90 (+1.24%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.13 -2.90 (-0.04%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,292.62 -46.44 (-3.47%)
Editas Medicine, Inc. (EDIT)
- Insider Monkey
12 Under-the-Radar Stocks With Massive Upside for 2024
In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024. If you want to skip our overview of shareholder ownership and how shares can jump if they come ‘over’ the radar instead of under, then you can jump ahead to 5 Under-the-Radar Stocks With Massive […]
- Zacks
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicin
